Drug Trial News

RSS

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

26 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

A new study published in the November 2011 issue of Stroke reveals some promising data on the positive effects of soy protein reducing the progression of clogged arteries in women who were within five years of menopause. This study was the largest and longest randomized controlled human study conducted to-date that directly investigated the efficacy of isolated soy protein consumption on the progression of atherosclerosis.

23 Sep 2011

Researchers to expand malaria vaccine study after initial trial yields encouraging results

Encouraged by early results of a study of an experimental malaria vaccine involving 45 children in Burkina Faso, researchers led by Pierre Druilhe at the Pasteur Institute in Paris are set to expand the clinical trial, resulting in a larger study involving 800 children in Mali, BBC News reports.

23 Sep 2011

Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae

Research has shown no evidence of a difference in clearance rates between patient self-treatment and treatment given by healthcare professional for verrucae.

23 Sep 2011

Levosimendan may effectively improve muscle function in patients with respiratory failure

Treatment with the calcium-sensitizing drug levosimendan may be effective in improving muscle function in patients with respiratory muscle weakness, which often accompanies chronic diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure, according to researchers in the Netherlands, who studied the effects of the drug on healthy volunteers.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

22 Sep 2011

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women

A soy germ-based nutritional supplement containing Natural S-equol significantly improved the appearance of crow's feet skin wrinkles of the outer corner of the eyes in Japanese menopausal women, suggesting that supplements containing Natural S-equol have potential to slow skin aging, according to data from a controlled pilot study simultaneously published online in the peer-review journal Menopause and presented in a poster session at the North American Menopause Society annual meeting.

22 Sep 2011

HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients

Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

21 Sep 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

Drug Trial News

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

Researchers to expand malaria vaccine study after initial trial yields encouraging results

Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae

Levosimendan may effectively improve muscle function in patients with respiratory failure

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Theraclone initiates TCN-032 Phase 1 trial in influenza A

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women

HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News